No Data
No Data
DuoRui Medicine (301075.SZ): intends to establish a holding subsidiary, DuoRui Oxygen Therapy.
Doray Medicine (301075.SZ) announced on August 1st that in order to fully utilize and integrate the advantages of various resources in accordance with the company's operation and global strategy, Tibet Doray Medicine Co., Ltd., Mr. Chen Liang, a natural person, and Hubei Jinlin Intelligence Technology Co., Ltd. (referred to as "Hubei Jinlin") jointly invested to establish Tibet Doray Oxygen Therapy Technology Co., Ltd. (referred to as "Doray Oxygen Therapy"). The registered capital of Doray Oxygen Therapy is 21 million yuan.
DuoRui Pharmaceutical (301075.SZ): Levofloxacin Sodium Chloride Injection has obtained the pharmaceutical registration certificate.
On July 8th, Gelunhui reported that Duori Pharmaceutical(301075.SZ) announced that its wholly-owned subsidiary, Hubei Duori Pharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Levofloxacin Sodium Chloride Injection. Levofloxacin Sodium Chloride Injection is indicated for the following infections caused by sensitive bacteria: acute bacterial bronchitis, community-acquired pneumonia (including community-acquired pneumonia caused by chlamydia and mycoplasma), hospital-acquired pneumonia, acute sinusitis, acute uncomplicated urethral infections, complicated urinary tract infections, and acute pyelonephritis.
Dorui Pharmaceuticals (301075.SZ) 2023 equity distribution: 1.25 yuan for every 10 shares
According to Zhitong Finance App News, Dorui Pharmaceutical (301075.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 1.25 in cash (tax included) to all shareholders for every 10 shares based on the company's total share capital. The share registration date for this equity distribution is: May 30, 2024, and the exempted dividend date is: May 31, 2024.
Dorui Pharmaceutical (301075.SZ): The repurchase was completed with a cumulative cost of 20.983,300 yuan to repurchase 1.044,500 shares
Glonghui, May 7, 丨 Dorui Pharmaceutical (301075.SZ) announced that as of April 30, 2024, the company had repurchased a total of 1.044,500 shares of the company's shares through a special stock repurchase securities account, accounting for 1.31% of the company's current total share capital. The highest transaction price was 21.10 yuan/share, the minimum transaction price was 18.21 yuan/share, and the total transaction amount was 20.9833 million yuan (excluding transaction fees). The company has completed this repurchase.
Dorui Pharmaceuticals (301075.SZ) announced first-quarter results, with a net loss of 2,5373 million yuan, an increase of 4.97% over the previous year
Dorui Pharmaceuticals (301075.SZ) released its report for the first quarter of 2024, with revenue of 784.574 million...
Dorui Pharmaceuticals (301075.SZ): 2023 net profit of 18.857,700 yuan, plans to distribute 10 to 1.25 yuan
On April 17, Ge Longhui Pharmaceutical (301075.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 334 million yuan, a year-on-year decrease of 16.64%; net profit attributable to shareholders of listed companies was 18.8507 million yuan, a year-on-year decrease of 8.05%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 5.258 million yuan, a year-on-year decrease of 34.96%; basic earnings per share of 0.24 yuan; it plans to distribute a cash dividend of 1.25 yuan (tax included) for every 10 shares to all shareholders.
No Data